Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) reported that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with osteoarthritis (OA) of the

Read the full 265 word article

User Sign In